Till startsida
University of Gothenburg
To content Read more about how we use cookies on gu.se


WINROP® history
We have done extensive laboratory work showing that insulin like growth factor 1 (IGF-1) which mediates growth is a major factor in the development of ROP (Hellström A et al Proceedings of the National Academy of Sciences, 2001).

Based on that finding we developed and published an algorithm WINROP® based on serial neonatal measurements of body weight, which predicts ROP development. The original article including IGF measurements prompted an editorial in Archives of Ophthalmology “Screening for Retinopathy of Prematurity- The Promise of New Approaches”.

The algorithm

The algorithm has now been further developed (web based, free of charge) and validated retrospectively on 50 children screened for ROP 2005-2007 at various Swedish neonathal wards in, Sweden. We found that WINROP® predicted early (mean 9 weeks before ROP needing treatment was detected by present screening routines) all infants who later developed proliferative ROP requiring treatment (sensitivity 100% and specificity 54%) (Löfqvist C et al Archives Ophthalmol 2009). In order to make WINROP® rapid and robust as well as more equipment-free we have revised the algorithm using only serial weight measurements. With this approach WINROP® predicted early all infants who later developed proliferative ROP requiring treatment and correctly identified 75% of those who did not develop proliferative ROP (Hellström A et al Pediatrics 2009), and thus would not need any ophthalmologic screening. In addition, we have validated WINROP® in a preterm population in Boston (n=375) indicating a 100% sensitivity and a 76% specificity (Wu C et al Archives Ophthalmol 2009). Applying these figures of reduced screening to the European preterm population the number of ophthalmological examinations could be safely reduced by 200,000 examinations/year, yet include 100% of infants requiring treatment for ROP. WINROP®  has been further validatet in multiple clinical settings international, see PUB Med for scientific publications.

New standard

In order to establish this as the new standard of care worldwide WINROP® is now validated in Sweden, Northamerica, Great Britain, Germany, Schwitzerland, Mexico, China, Southkorea, Netherlands, India, Scotland, Canada and Brasil. WINROP® is now up and running in 56 countries, used by 348 caregivers in 215 different sites (2018). The use of WINROP® for screening would identify early children at risk and could lead to early interventions.  Globally health personnel could focus on the right patients at the right time. Thus, WINROP® (simple to perform with minimal training) would supply a descision making tool in ROP screening -an approach that is clearly cost effective and makes better use of resources.

Page Manager: Carola Pfeiffer Mosesson|Last update: 6/25/2018

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?

Denna text är utskriven från följande webbsida:
Utskriftsdatum: 2020-08-14